Your session is about to expire
← Back to Search
Anti-tumor antibiotic
Chemotherapy for Liver and Bile Duct Cancer
Phase 2
Waitlist Available
Research Sponsored by Brown University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Performance status: ECOG 0-2
Histologically confirmed carcinoma of the liver or bile ducts including hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing a new chemotherapy drug to see if it is effective in treating patients with liver or bile duct cancer.
Who is the study for?
This trial is for adults with liver or bile duct cancer, including hepatocellular carcinoma and cholangiocarcinoma. Participants must have a disease that can be measured by CT scan. They should not be severely ill (ECOG performance status of 0-2), have low blood cell counts, severe liver damage, poor kidney function, weak heart muscles, or be pregnant/nursing without effective contraception.Check my eligibility
What is being tested?
The study is testing the effectiveness of liposomal doxorubicin—a chemotherapy drug packaged in fat bubbles to better target cancer cells—in patients with various types of liver or bile duct cancers.See study design
What are the potential side effects?
Liposomal doxorubicin may cause side effects such as fatigue, nausea, hair loss, mouth sores, and low blood cell counts which can increase infection risk. It might also lead to heart problems due to its effect on cardiac muscle.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am able to get out of my bed or chair and move around.
Select...
My cancer is in the liver, bile ducts, or gallbladder.
Select...
I am 18 years old or older.
Select...
My creatinine level is 3.0 mg/dL or lower.
Select...
My bilirubin levels are below 3 mg/dL and I don't have severe liver disease.
Select...
My heart pumps blood effectively with an ejection fraction of at least 45%.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Brown UniversityLead Sponsor
456 Previous Clinical Trials
558,318 Total Patients Enrolled
1 Trials studying Liver Cancer
41 Patients Enrolled for Liver Cancer
Howard Safran, MDStudy ChairBrown University
30 Previous Clinical Trials
907 Total Patients Enrolled
1 Trials studying Liver Cancer
41 Patients Enrolled for Liver Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am able to get out of my bed or chair and move around.My cancer is in the liver, bile ducts, or gallbladder.It has been over 4 weeks since my last chemotherapy session.I am 18 years old or older.I have never been treated with doxorubicin.I have had radiotherapy before.My creatinine level is 3.0 mg/dL or lower.My bilirubin levels are below 3 mg/dL and I don't have severe liver disease.My heart pumps blood effectively with an ejection fraction of at least 45%.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still openings for participants in this experiment?
"According to clinicaltrials.gov, the trial is no longer enrolling patients as it was last modified on December 18th 2013. However, there are 446 other medical studies actively looking for participants at this point in time."
Answered by AI
Would this remedy be considered a secure choice for individuals?
"The safety of this treatment is rated as a 2, indicating that clinical data has demonstrated its relative safety but no efficacy studies have been conducted yet."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger